Ferrous Fumarate

證據等級: L5

預測適應症: 10 個

Ferrous Fumarate: From Iron-Deficiency Anaemia to Non-syndromic Esophageal Malformation

One-Sentence Summary

Ferrous fumarate is a conventional oral iron salt whose general pharmacological role is treating iron-deficiency anaemia; no TFDA-specific approved indication text was available in this evidence pack. The TxGNN model’s top-ranked prediction for this drug is non-syndromic esophageal malformation, a congenital structural anomaly, with a very high similarity score (99.49%) but zero clinical trials and zero publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Iron-deficiency anaemia (general pharmacological use; no TFDA-approved indication text available in evidence pack)
Predicted New Indication	Non-syndromic esophageal malformation
TxGNN Prediction Score	99.49%
Evidence Level	L5
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, ferrous fumarate is a haematinic agent used to replenish iron stores and correct iron-deficiency anaemia; its efficacy in that setting is well established.

However, for this specific top-ranked prediction, the mechanistic case is weak. Non-syndromic esophageal malformation is a congenital structural anomaly of embryological origin, not a disorder of iron metabolism or haematopoiesis. The evidence pack’s own rationale is explicit on this point: there is no plausible biological connection between iron-ion physiology and structural oesophageal development, and the prediction rests purely on TxGNN embedding similarity with no corroborating clinical or literature evidence.

Given the absence of any supporting trials or publications, this candidate should be treated as an unverified model output rather than a mechanistically grounded repurposing hypothesis.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Australia Market Information

Ferrous fumarate is not currently registered on the ARTG (Australian Register of Therapeutic Goods) — 0 entries found in this evidence pack.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction carries a high TxGNN similarity score but has no clinical trial or literature support, and no plausible mechanistic link between iron supplementation and a congenital oesophageal structural anomaly. This does not meet the threshold for further evaluation.

To proceed, the following is needed:

Preclinical or mechanistic evidence linking iron metabolism to oesophageal structural development
TFDA-approved product label / warnings and contraindications (currently blocked — see data gap DG001)
Confirmed mechanism of action data (currently missing — see data gap DG002)

Note: Other TxGNN-predicted indications for ferrous fumarate in this same evaluation batch have materially stronger support and may be more productive to evaluate separately — notably Plummer-Vinson syndrome (L4 evidence, direct case-report use of ferrous fumarate as standard-of-care) and perinatal disease / iron-deficiency anaemia in pregnancy (L2 evidence, multiple completed Phase 2–4 trials).

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.